Leadless, intracardiac pacemakers are a major innovation in the management of bradyarrhythmia. Both safety and feasibility of leadless pacing have been assessed in acute settings and mid-term follow-up showing a significant reduction of pacing-related complications as compared with standard transvenous pacemakers. There are many advantages of the leadless approach including a reduction of infection risk and malfunction due to the absence of transvenous leads and the pacemaker pocket. Patients at high risk of endocarditis or pocket failure, with compromised venous access, can benefit from the leadless approach. In this review article, the relevant implant indications for leadless pacemaker and patient populations are described.